Diffuse large B‐cell lymphoma (DLBCL) is the most common haematopoietic tumour in dogs and recognized as clinical model for its human counterpart. Recently, neutrophil‐to‐lymphocyte (NLR) and lymphocyte‐to‐monocyte (LMR) ratios have been shown to predict time‐to‐progression (TTP) and lymphoma‐specific survival (LSS) in dogs with DLBCL treated with CHOP‐based chemotherapy. We retrospectively evaluated in 59 dogs diagnosed with DLBCL the prognostic value of haematological parameters and derived ratios: NLR, LMR, platelet‐to‐lymphocyte (PLR) and platelet‐to‐neutrophil (PNR) ratios for TTP, LSS and associated secondary end‐points (time‐to‐progression‐rate [TTPR] and lymphoma‐specific survival‐rate [LSSR]) as rates at 180 and 365 days. PNR is an independent prognostic marker (p ≤ .001) for TTPR/180 and 365 days, dogs with a PNR above 0.032 were more likely to progress before 180 days (sensitivity 46.5%, specificity 87.5%, p = .004). On univariate analysis, NLR showed a prognostic significance for LSSR/180 (p = .006) and LSSR/365 (p = .009). A baseline NLR value below 7.45 was positively associated with survival at 180 days (sensitivity 52%, specificity 85.3%, p = .025). The presence of substage b, was associated with early progression and decreased survival at 180 days (p = .031). Anaemia significantly reduced LSSR at 365 days (p = .028). This is the first study evaluating PLR and PNR in canine DLBCL and demonstrates that PNR could be a predictor of early lymphoma progression. Since peripheral blood cell composition can be affected by several non‐oncological causes, the development of larger multicenter studies with homogeneous inclusion criteria could help to better determine the true predictive values of blood cell ratios in dogs' DLBCL treated with CHOP chemotherapy.

中文翻译：

---

外周血细胞比率作为 CHOP 方案治疗犬弥漫性大 B 细胞淋巴瘤的预后因素

弥漫性大 B 细胞淋巴瘤 (DLBCL) 是犬中最常见的造血肿瘤，并被认为是其人类对应物的临床模型。最近，中性粒细胞与淋巴细胞 (NLR) 和淋巴细胞与单核细胞 (LMR) 的比率已被证明可以预测接受 CHOP 治疗的 DLBCL 犬的进展时间 (TTP) 和淋巴瘤特异性存活率 (LSS)化疗。我们回顾性评估了 59 只诊断为 DLBCL 的狗的血液学参数和衍生比率的预后价值：NLR、LMR、血小板与淋巴细胞 (PLR) 和血小板与中性粒细胞 (PNR) 的比率，用于 TTP、LSS 和相关的次级终末期。点（进展时间率 [TTPR] 和淋巴瘤特异性存活率 [LSSR]）作为 180 天和 365 天的比率。PNR 是一个独立的预后标志物 ( p ≤ .001) 对于 TTPR/180 天和 365 天，PNR 高于 0.032 的狗更有可能在 180 天之前进展（敏感性 46.5%，特异性 87.5%，p  = .004）。在单变量分析中，NLR 显示出 LSSR/180 ( p  = .006) 和 LSSR/365 ( p  = .009) 的预后意义。低于 7.45 的基线 NLR 值与 180 天的存活率呈正相关（敏感性 52%，特异性 85.3%，p  = .025）。b亚阶段的存在与早期进展和 180 天生存率降低有关 ( p  = .031)。贫血在 365 天时显着降低 LSSR ( p = .028)。这是第一项评估犬 DLBCL 中的 PLR 和 PNR 的研究，并证明 PNR 可能是早期淋巴瘤进展的预测因子。由于外周血细胞组成可能受到几种非肿瘤原因的影响，因此开展具有同质纳入标准的大型多中心研究可能有助于更好地确定接受 CHOP 化疗的犬 DLBCL 中血细胞比率的真实预测值。